Your GLP-1 maintenance dose is the lowest amount of medication that holds your weight and your metabolic markers at the result you and your clinician agreed on. It is rarely the highest dose you can tolerate and it is almost never the number a discount telehealth page would sell you by default. If you are on Wegovy, Zepbound, Ozempic or Mounjaro and your dose keeps climbing while your monthly bill climbs with it, this guide explains how a clinician is supposed to find the dose you actually need and how to tell whether anyone is doing that work at all.
- A maintenance dose is defined by the result it holds, never by the top of the titration ladder.
- Trial evidence shows most of the benefit arrives before the highest dose while side effects keep rising with each step.
- Hunger returning, a plateau and a dose that stops agreeing with you are clinical signals to read, not problems to silence with a bigger dose.
- Stepping down with supervision is different from stopping and the withdrawal trials do not describe the first one.
- Our fee is flat at $299 a month precisely because a dose decision should never be a revenue event.
What a maintenance dose actually means
Titration ladders exist because your body needs time to adapt to each step of a GLP-1. The published schedules for semaglutide and tirzepatide move up every four weeks or so and marketing has taught patients to read that ladder as a progress bar toward the top. A clinician reads it differently. Every step is a question. Does the result justify this amount of medicine, at this level of side effects, for this person? When the answer is yes, the ladder stops and what you are standing on becomes your GLP-1 maintenance dose.
That definition matters because it changes what success looks like. The goal is not to reach 2.4 mg of semaglutide or 15 mg of tirzepatide. The goal is the lowest dose that holds your weight trend, your HbA1c and your other markers in the range you and your clinician set together. For some people that is the top dose. For many it is a middle step held for a year or longer. If nobody has told you where your ladder stops or what would justify the next rung, the treatment plan is missing its most important sentence.
What the trial evidence says about the top dose
The registration trials tested the top dose, so the top dose gets the headlines. The dose-response curves underneath those headlines tell a more useful story. In the semaglutide and tirzepatide programs, a large share of the total weight loss and glycemic improvement arrives before the highest dose, while gastrointestinal side effects continue to rise with each step. STEP 1 established the headline figure of roughly 15 percent average weight loss at 68 weeks for semaglutide 2.4 mg and the titration data behind it show meaningful results well before the final step. Individual results vary widely and the figures are averages from trials, not promises for any individual.
There is also a practical argument for the lowest effective dose that has nothing to do with side effects. The strongest appetite suppression is not free. It makes adequate protein harder to eat, it can drain the strength out of your training and it pushes the composition of your weight loss in the wrong direction. We cover that arithmetic in our guide to preventing muscle loss on a GLP-1. A dose you can eat enough protein under usually produces a better body composition than a dose you cannot, even at a slightly slower headline number.
At every step of the ladder, someone should be able to answer what the next dose is expected to add, what it will cost you in side effects and protein intake and what evidence would say the current dose is already enough. If those questions have no answers, the titration is running on autopilot.
The signals a clinician reads when choosing your dose
Finding a maintenance dose is a pattern-reading exercise across three or four data streams. None of them is the scale alone.
Hunger and food noise. A workable dose quiets food noise enough that your plan is livable. A dose that eliminates appetite entirely makes protein and resistance work nearly impossible, which we treat as a reason to hold or step down rather than a sign the medicine is working extra well.
Weight and waist trend. After the initial rapid phase, a steady decline of a fraction of a percent of body weight per week is the healthy rhythm. Rapid loss in month four or five usually means the dose outran your habits and your lean mass is paying for it.
Metabolic markers. Our Biomarker Audit repeats HbA1c, insulin markers, lipids, ApoB, hs-CRP and the full hormone and thyroid panels every 90 days. A1c and ApoB moving the right way at a middle dose is evidence that the current dose is doing the metabolic work, whatever the scale says.
Side effects and strength. Nausea that never fully resolves, fatigue in the gym or strength drifting downward are all dose-relevant signals, because they change what you can actually do with the plan.
What holds a dose where it is vs what moves it
| Signal | Holds the current dose | Moves the dose down | Moves the dose up |
|---|---|---|---|
| Appetite | Plan feels livable | Cannot hit protein targets | Food noise is running your week |
| Weight trend | Steady, expected decline | Loss is unnaturally fast | Loss has fully stalled for months |
| Markers | A1c and ApoB improving | Markers fine but strength falling | A1c drifting up despite adherence |
| Side effects | Mild and settling | Persistent nausea or fatigue | None and tolerance is proven |
Stepping down is not the same as stopping
The most misused statistic in this space comes from the withdrawal trials. In STEP 4, participants who stopped semaglutide after a year of treatment regained a substantial share of the weight over the following year. Discount platforms quote studies like that to argue you should never reduce a dose, because any change is framed as quitting. That is a false choice.
Stopping treatment entirely removes both the appetite effect and the clinical relationship at the same time. Stepping down under supervision changes one variable while the protein targets, the training and the quarterly labs stay in place. If your markers hold and your weight holds at a lower dose, you have found the dose you actually need. If hunger surges and the trend reverses, the answer is a move back up, made early, with data. Either outcome is a normal experiment in good care. What the trials warn against is abandoning monitoring, not adjusting a dose with a clinician watching.
Why dose discipline is rare and how our model makes it safe
Here is the part that is structural rather than clinical. In most of telehealth weight loss, the provider also sells the medication and higher doses cost the patient more per month. When the platform that advises you earns more from the 15 mg pen than the 5 mg pen, every ambiguous decision in your titration quietly favors the higher dose. We are not accusing any named company of anything. We are describing an incentive and you can test it by asking your current provider in writing what their financial interest is in your next dose increase.
Our structure removes the question. Membership in our Cardiometabolic Optimization program is one flat $299 a month after a first charge of $598 that covers the first two months together. The $598 is a single charge covering your clinical intake, your first Biomarker Audit and two months of clinical care while your protocol is built. From month three the fee is $299 a month, month to month and you can cancel anytime after the initial commitment. That fee covers the doctor and the labs. Medicine is a separate charge, billed by your pharmacy at pharmacy cost, with zero markup, no molecule upcharge and no dose-escalation fee from us. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger.
A common objection we hear is straightforward. If the medicine is billed at cost either way, why pay a membership at all? The honest answer is that the medicine was never the hard part. The hard part is the clinician who reads your quarterly panel, notices your protein slipping before your muscle does and tells you plainly to hold the dose you are on. That judgment is what the fee buys and it is deliberately priced flat so that the advice to step down costs us nothing and the advice to step up earns us nothing.
Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. Only branded, FDA-approved medication is prescribed, including Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo. Compounded GLP-1 is never prescribed under any circumstance.
What to ask at your next dose conversation
You can run your own titration audit with four questions and a good clinician will welcome every one of them. What result is my current dose holding, in numbers? What would the next dose add to that, with what side effect cost? What evidence would tell us this dose is already enough? And who at your practice profits if I go up? If the answers are specific, you have found your maintenance dose or you are on the way to it. If the answers are vague, the ladder is running on autopilot and you deserve a pilot.
If you want a clinician whose income does not change with your dose, check your eligibility or read how we think about your lowest effective dose across a whole protocol.
FAQ
What is a GLP-1 maintenance dose? It is the lowest dose that holds your agreed result, meaning your weight trend and your metabolic markers, without side effects that break your protein intake or your training. It is found by reading those signals at each titration step rather than by climbing to the top of the schedule by default.
How long does it take to find a maintenance dose? Most people reach a workable maintenance step within three to six months, because the standard titration pauses at each dose for about four weeks. A middle dose held for a year is a normal outcome and is not a failure of treatment.
Will I regain the weight if I lower my dose? Not automatically. The withdrawal trials describe stopping treatment and monitoring together. A supervised step-down that keeps your protein targets, resistance training and quarterly labs in place changes one variable at a time and the move can be reversed early if hunger and weight trend reverse.
Is the highest dose always more effective? Trials show larger average weight loss at higher doses, but a large share of the benefit arrives before the top step while side effects keep rising. The practical question is what result your current dose holds and whether the next step justifies its cost in side effects and lost protein capacity.
Does GoodLife Health charge more for higher GLP-1 doses? No. Membership is a flat $299 a month after a $598 first charge that covers the first two months together and the fee never changes with dose or medication. The medicine is billed separately by your pharmacy at pharmacy cost with zero markup.
Do you prescribe compounded GLP-1s? Never. Only branded, FDA-approved medication is prescribed under our clinical protocols, including Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo.
Can I switch to maintenance if my current platform keeps raising my dose? Yes. Bring your dosing history and any lab results you have and a clinician can review whether your current dose is holding your markers or whether a step down is clinically reasonable. The decision belongs to your clinician and you, never to a billing schedule.
Related Reading
- How to prevent muscle loss on Ozempic
- Medical weight loss at GoodLife Health
- Biomarker audits vs standard blood tests
- Cardiometabolic optimization: the definitive guide
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, New England Journal of Medicine). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4, JAMA). 2021. pubmed.ncbi.nlm.nih.gov/33951169/
- Protein intake recommendations for adults (NIH Office of Dietary Supplements). 2024. ods.od.nih.gov/factsheets/Protein-HealthProfessional/